AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 221 min read$SOPH

Muken Ross sold $4K of SOPH

Muken Ross (Chief Executive Officer) sold 422 shares of SOPHiA GENETICS SA (SOPH) at $8.33 on 2026-09-21 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Muken Ross
Published Sep 22, 2026, 8:02 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 22, 2026, 8:28 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$SOPH
Neutral
high confidence
Mentioned
$SOPH
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SOPHNeutralLow
01

Why it matters

The disclosed sale is small and unlikely to move SOPHiA GENETICS stock.

02

Market read

Routine insider sell with minimal market relevance.

03

What to watch

Potential tax planning or portfolio rebalancing could be the motive, not company performance.

Relevance 2/10Novelty 2/10Timing: transaction dated 2026-09-21

Background

Form 4 filings disclose insider transactions; routine sales under $1M are common and usually non‑material.

Company-level read

Ticker impact

$SOPHNeutralHigh confidence
Context

CEO Muken Ross sold 422 shares for $3,515 via a 10b5-1 plan, reducing his stake to 670,229 shares.

Expected impact

No significant move; possible slight downward pressure.

Evidence & confidence

The sale amount is trivial relative to holdings and market cap; such routine sales rarely affect stock price.

Market effects

Sector

No broader sector impact; biotech sector unchanged.

Regional

Limited to Swiss/US biotech investors; negligible.

Global

None

Counterpoint

What could challenge this read

If the insider is offloading shares ahead of undisclosed negative news, the stock could face downside.

Key entities

  • Company
    SOPHiA GENETICS SA

    Swiss biotech firm listed on NASDAQ under SOPH.

  • Person
    Muken Ross

    Chief Executive Officer of SOPHiA GENETICS.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

SOPH insider trading history →

Related articles

AUG 11
$SOPHMedAI 8/10

SOPHiA GENETICS (SOPH) Q2 2026 Earnings Call Transcript

SOPHiA GENETICS SA (SOPH) reported Q2 2026 revenue of $23.3 million, up 27%, and an adjusted EBITDA loss of $8.8 million. Platform analysis volume rose 22% to 115,000 patient analyses. Management raised full-year revenue guidance to $94 million to $96 million and reaffirmed adjusted EBITDA loss of $29 million to $32 million, citing U.S. in-house testing demand and biopharma growth.

fool.com6 min
AUG 4
$SOPHHighAI 9/10

SOPHiA GENETICS Reports Second Quarter 2026 Results

SOPHiA GENETICS (Nasdaq: SOPH) reported Q2 2026 revenue of $23.3 million, up 27% year over year, with gross margin of 64.6% reported and 72.1% adjusted. Net loss was $22.4 million and adjusted EBITDA loss was $8.8 million, improving 27%. The company raised 2026 revenue guidance to $94-$96 million and signed AstraZeneca companion diagnostic programs.

prnewswire.com6 min
AUG 4
$SOPHMed

SOPHiA GENETICS SA (SOPH): Financial results for Q2 2026

SOPHiA GENETICS SA (SOPH) furnished an SEC Form 6-K — earnings release. Exhibit 99.3 SOPHiA GENETICS Reports Second Quarter 2026 Results BOSTON, United States and ROLLE, Switzerland, August 4, 2026 — SOPHiA GENETICS (Nasdaq: SOPH), a global leader in AI-driven precision medicine, today reported financial results for the second quarter ended June 30,

SEC EDGAR 6-K2 min
AUG 4
$SOPHMed

SOPHiA GENETICS Enters Collaboration to Develop Companion Diagnostics for Precision Oncology Therapies

SOPHiA GENETICS (NASDAQ: SOPH) said it entered a multi-year collaboration with AstraZeneca to develop, validate, and deploy two companion diagnostics for precision oncology therapies. SOPHiA will advance its Solid Tumor decentralized CDx and develop a Hematological Oncology application for blood cancer. The programs aim to support commercialization of AstraZeneca therapies.

finanznachrichten.de4 min